What Cardiologists Should Know About Essential Thrombocythemia and Acute Myocardial Infarction: Report of Two Cases and Advanced Heart Failure Therapies Considerations

Overview

Journal Int Med Case Rep J

Publisher Dove Medical Press

Specialty General Medicine

Date 2019 Sep 10

PMID 31496834

Citations 5

Authors

Marie-Camille Soucy-Giguere

Pierre Yves Turgeon

Mario Senechal

Affiliations

Soon will be listed here.

Abstract

We present the cases of two young male patients aged 22 and 31 without prior medical history nor cardiovascular risk factors, who presented to the hospital with large anterior ST-elevation myocardial infarction (STEMI). Urgent coronary angiography revealed acute thrombotic occlusion of the proximal left anterior descending artery in both patients. Persistent thrombocytosis was noted and subsequent investigations led to the diagnosis of essential thrombocythemia (ET) with positive JAK2-V617F mutation. Myocardial infarction as a first clinical manifestation of ET is rare but must be considered in patients without cardiovascular risk factors who show persistent thrombocytosis. In young patients without risk factors, there may be great delays before the diagnosis of STEMI is made. Longer time to revascularization of extensive STEMI is associated with adverse outcomes and cardiogenic shock which can lead to advanced therapies like heart transplant and left ventricular assist device (LVAD). Considering the favorable long-term prognosis of patients with ET, advanced therapies may be a valuable option in the presence of severe left ventricular dysfunction.

Citing Articles

A Case of acute Myocardial Infarction in a Patient with Essential Thrombocythaemia Treated with Anagrelide.

Yetiskul E, Nisar A, Khan S, Qaqish F, Khan D, Bershadskiy A Eur J Case Rep Intern Med. 2024; 11(3):004340.

PMID: 38455691 PMC: 10917403. DOI: 10.12890/2024_004340.

Acute myocardial infarction in myeloproliferative neoplasms.

Manan M, Kipkorir V, Nawaz I, Waithaka M, Srichawla B, Gaman A World J Cardiol. 2023; 15(11):571-581.

PMID: 38058401 PMC: 10696206. DOI: 10.4330/wjc.v15.i11.571.

Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist.

Kuipers R, Kok L, Virmani R, Tefferi A Neth Heart J. 2023; 31(10):371-378.

PMID: 36757576 PMC: 10516821. DOI: 10.1007/s12471-023-01757-4.

Case Report: A Rare Case of Acute Anterior Myocardial Infarction Simultaneously Associated With Aortic Mural Thrombosis Due to Essential Thrombocytosis.

Ye S, Xia W, Chen P Front Cardiovasc Med. 2022; 9:840906.

PMID: 35282362 PMC: 8904716. DOI: 10.3389/fcvm.2022.840906.

Acute Limb Ischemia in the Young: A Rare Case of Essential Thrombocytosis.

Nugroho J, Gunadi R Case Rep Cardiol. 2021; 2021:2563578.

PMID: 34845429 PMC: 8627342. DOI: 10.1155/2021/2563578.

References

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

Vianello F, Cella G, Osto E, Ballin A, Famoso G, Tellatin S . Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?. Am J Hematol. 2014; 90(2):109-13. DOI: 10.1002/ajh.23881. View

Derks A, Bloemer M . Essential thrombocythaemia as cause of myocardial infarction. Neth Heart J. 2015; 9(9):383-385. PMC: 2504434. View

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H . A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012; 120(6):1197-201. DOI: 10.1182/blood-2012-01-403279. View

Daya S, Gowda R, Landis W, Khan I . Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. Angiology. 2004; 55(3):319-23. DOI: 10.1177/000331970405500312. View

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F . Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22):5857-9. DOI: 10.1182/blood-2011-02-339002. View

Risch L, Pihan H, Zeller C, Huber A . ET gets HIT--thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). Blood Coagul Fibrinolysis. 2000; 11(7):663-7. DOI: 10.1097/00001721-200010000-00011. View

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M . Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004; 117(10):755-61. DOI: 10.1016/j.amjmed.2004.06.032. View

Nanavati A, Patel N, Burke J . Thrombocytosis and coronary occlusion. JACC Cardiovasc Interv. 2012; 5(6):e18-9. DOI: 10.1016/j.jcin.2011.12.018. View

10.

Chim C, Kwong Y, Lie A, Ma S, Chan C, Wong L . Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005; 165(22):2651-8. DOI: 10.1001/archinte.165.22.2651. View

11.

Bildirici U, Celikyurt U, Ural E . Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female. Clin Cardiol. 2009; 32(2):104-5. PMC: 6653693. DOI: 10.1002/clc.20426. View

12.

Reikvam H, Tiu R . Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2011; 26(4):563-71. DOI: 10.1038/leu.2011.314. View

13.

Haddad M, Veinot J, Masters R, Hendry P . Essential thrombocytosis causing a massive myocardial infarction. Cardiovasc Pathol. 2003; 12(4):216-8. DOI: 10.1016/s1054-8807(03)00055-3. View

14.

Wolanskyj A, Lasho T, Schwager S, McClure R, Wadleigh M, Lee S . JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005; 131(2):208-13. DOI: 10.1111/j.1365-2141.2005.05764.x. View

15.

Mehra M, Canter C, Hannan M, Semigran M, Uber P, Baran D . The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016; 35(1):1-23. DOI: 10.1016/j.healun.2015.10.023. View

16.

Spectre G, Kalish Y, Schliamser L, Varon D . Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication?. Am J Hematol. 2008; 83(5):420-3. DOI: 10.1002/ajh.21128. View

17.

Houston D . Heparin-induced thrombocytopenia without thrombocytopenia in a patient with essential thrombocythemia. Am J Hematol. 2000; 65(4):331-2. DOI: 10.1002/1096-8652(200012)65:4<331::aid-ajh23>3.0.co;2-2. View

18.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M . Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011; 29(23):3179-84. DOI: 10.1200/JCO.2010.34.5298. View

19.

Rossi C, Randi M, Zerbinati P, Rinaldi V, Girolami A . Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med. 1998; 244(1):49-53. DOI: 10.1046/j.1365-2796.1998.00314.x. View

20.

Rumi E, Cazzola M . How I treat essential thrombocythemia. Blood. 2016; 128(20):2403-2414. DOI: 10.1182/blood-2016-05-643346. View